Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Inmune Bio total assets
Total assets on the balance sheet at the end of each period.
Inmune Bio's total assets was $26.85M at Jun 30, 2026. For fiscal 2025 it was $32.35M, down 18.2% from the year before. The highest annual figure on record is $99.95M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.35M | -18.2% |
| FY2024 | Dec 31, 2024 | $39.56M | -30.6% |
| FY2023 | Dec 31, 2023 | $57.00M | -30.3% |
| FY2022 | Dec 31, 2022 | $81.80M | -18.2% |
| FY2021 | Dec 31, 2021 | $99.95M | +145.8% |
| FY2020 | Dec 31, 2020 | $40.66M | +66.1% |
| FY2019 | Dec 31, 2019 | $24.47M | +40.9% |
| FY2018 | Dec 31, 2018 | $17.36M | -5.7% |
| FY2017 | Dec 31, 2017 | $18.41M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.85M | -28.8% |
| Q1 FY2026 | Mar 31, 2026 | $25.82M | -31.7% |
| Q4 FY2025 | Dec 31, 2025 | $32.35M | -18.2% |
| Q3 FY2025 | Sep 30, 2025 | $33.36M | -36.8% |
| Q2 FY2025 | Jun 30, 2025 | $37.68M | -28.2% |
| Q1 FY2025 | Mar 31, 2025 | $37.80M | -19.3% |
| Q4 FY2024 | Dec 31, 2024 | $39.56M | -30.6% |
| Q3 FY2024 | Sep 30, 2024 | $52.78M | -15.8% |
| Q2 FY2024 | Jun 30, 2024 | $52.45M | -24.8% |
| Q1 FY2024 | Mar 31, 2024 | $46.83M | -36.7% |
| Q4 FY2023 | Dec 31, 2023 | $57.00M | -30.3% |
| Q3 FY2023 | Sep 30, 2023 | $62.70M | -25.2% |
| Q2 FY2023 | Jun 30, 2023 | $69.72M | -20.6% |
| Q1 FY2023 | Mar 31, 2023 | $73.98M | -21.6% |
| Q4 FY2022 | Dec 31, 2022 | $81.80M | -18.2% |
| Q3 FY2022 | Sep 30, 2022 | $83.80M | -22.2% |
| Q2 FY2022 | Jun 30, 2022 | $87.81M | +44.7% |
| Q1 FY2022 | Mar 31, 2022 | $94.35M | +43.2% |
| Q4 FY2021 | Dec 31, 2021 | $99.95M | +145.8% |
| Q3 FY2021 | Sep 30, 2021 | $107.67M | +151.5% |
| Q2 FY2021 | Jun 30, 2021 | $60.70M | +163.4% |
| Q1 FY2021 | Mar 31, 2021 | $65.87M | +178.2% |
| Q4 FY2020 | Dec 31, 2020 | $40.66M | +66.1% |
| Q3 FY2020 | Sep 30, 2020 | $42.82M | +68.6% |
| Q2 FY2020 | Jun 30, 2020 | $23.05M | -16.3% |
| Q1 FY2020 | Mar 31, 2020 | $23.68M | +0.1% |
| Q4 FY2019 | Dec 31, 2019 | $24.47M | +40.9% |
| Q3 FY2019 | Sep 30, 2019 | $25.40M | +37.9% |
| Q2 FY2019 | Jun 30, 2019 | $27.53M | – |
| Q1 FY2019 | Mar 31, 2019 | $23.64M | – |
| Q4 FY2018 | Dec 31, 2018 | $17.36M | – |
| Q4 FY2017 | Dec 31, 2017 | $18.41M | – |
See a number that looks wrong?